Ambit, Cephalon Pen Kinase Drug-Discovery, Development Alliance | GenomeWeb
NEW YORK (GenomeWeb News) — Ambit Biosciences today said it will combine its KinomeScan-driven discovery technology with Cephalon's chemistry and discovery and development chops to help develop kinase inhibitors.
 
Terms of the deal call for Ambit to screen a “large” library of Cephalon’s kinase-focused compounds to generate “nearly a million data points,” Ambit said. In return, Cephalon will pay Ambit $18 million in an up-front fee to access its KinomeScan technology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.